{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:04:45Z","timestamp":1768896285621,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-014-2692-7","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T14:39:12Z","timestamp":1395931152000},"source":"Crossref","is-referenced-by-count":21,"title":["Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate"],"prefix":"10.1007","author":[{"given":"J. P.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. R.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. G.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bonnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. B.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Recknor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"key":"2692_CR1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","volume":"80","author":"RR Recker","year":"2005","unstructured":"Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856\u2013861","journal-title":"Mayo Clin Proc"},{"key":"2692_CR2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-010-1335-x","volume":"22","author":"S Lee","year":"2011","unstructured":"Lee S, Glendenning P, Inderjeeth CA (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741\u2013753","journal-title":"Osteoporos Int"},{"key":"2692_CR3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"2692_CR4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cotte","year":"2010","unstructured":"Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u2013155","journal-title":"Osteoporos Int"},{"key":"2692_CR5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00198-011-1729-4","volume":"23","author":"J Devine","year":"2012","unstructured":"Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, Davies W (2012) A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int 23:1415\u20131424","journal-title":"Osteoporos Int"},{"key":"2692_CR6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.amjmed.2009.05.017","volume":"123","author":"BA Briesacher","year":"2010","unstructured":"Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med 123:275\u2013280","journal-title":"Am J Med"},{"key":"2692_CR7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008","journal-title":"Osteoporos Int"},{"key":"2692_CR8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3\u2013S13","journal-title":"Am J Med"},{"key":"2692_CR9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00198-008-0586-2","volume":"19","author":"JA Sunyecz","year":"2008","unstructured":"Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM (2008) Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 19:1421\u20131429","journal-title":"Osteoporos Int"},{"key":"2692_CR10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"2692_CR11","doi-asserted-by":"crossref","unstructured":"Finigan J, Greenfield DM, Blumsohn A, Hannon RA, Peel NF, Jiang G, Eastell R (2008) Risk factors for vertebral and nonvertebral fracture over 10\u00a0years: a population-based study in women. J Bone Miner Res 23:75\u201385","DOI":"10.1359\/jbmr.070814"},{"key":"2692_CR12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00198-006-0310-z","volume":"18","author":"SH Gehlbach","year":"2007","unstructured":"Gehlbach SH, Avrunin JS, Puleo E, Spaeth R (2007) Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 18:805\u2013810","journal-title":"Osteoporos Int"},{"key":"2692_CR13","doi-asserted-by":"crossref","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5\u00a0mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u2013128","DOI":"10.1016\/j.bone.2007.03.011"},{"key":"2692_CR14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","volume":"332","author":"SR Cummings","year":"1995","unstructured":"Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767\u2013773","journal-title":"N Engl J Med"},{"key":"2692_CR15","doi-asserted-by":"crossref","unstructured":"Nevitt MC, Cummings SR, Stone KL et al (2005) Risk factors for a first-incident radiographic vertebral fracture in women > or =65\u00a0years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131\u2013140","DOI":"10.1359\/jbmr.2005.20.1.131"},{"key":"2692_CR16","unstructured":"WHO (2003) Adherence to long-term therapies: evidence for action. World Health Organization. http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_report\/en\/ Accessed 28 Oct 2013"},{"key":"2692_CR17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinthera.2012.02.002","volume":"34","author":"DW Dempster","year":"2012","unstructured":"Dempster DW, Lambing CL, Kostenuik PJ, Grauer A (2012) Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 34:521\u2013536","journal-title":"Clin Ther"},{"key":"2692_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","volume":"47","author":"HK Genant","year":"2010","unstructured":"Genant HK, Engelke K, Hanley DA et al (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47:131\u2013139","journal-title":"Bone"},{"key":"2692_CR19","doi-asserted-by":"crossref","unstructured":"Keaveny T, McClung M, Genant H et al (2014) Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Mineral Res 29:158\u2013165","DOI":"10.1002\/jbmr.2024"},{"key":"2692_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","volume":"49","author":"PJ Kostenuik","year":"2011","unstructured":"Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151\u2013161","journal-title":"Bone"},{"key":"2692_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/GME.0b013e318267f909","volume":"20","author":"JA Simon","year":"2013","unstructured":"Simon JA, Recknor C, Moffett AH Jr et al (2013) Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 20:130\u2013137","journal-title":"Menopause"},{"key":"2692_CR22","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291\u20131299","journal-title":"Obstet Gynecol"},{"key":"2692_CR23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354","journal-title":"Bone"},{"key":"2692_CR24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1345\/aph.1Q652","volume":"46","author":"K Reynolds","year":"2012","unstructured":"Reynolds K, Viswanathan HN, O'Malley CD et al (2012) Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 46:659\u2013670","journal-title":"Ann Pharmacother"},{"key":"2692_CR25","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96:1727\u20131736","journal-title":"J Clin Endocrinol Metab"},{"key":"2692_CR26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","volume":"27","author":"MR McClung","year":"2012","unstructured":"McClung MR, Boonen S, Torring O et al (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27:211\u2013218","journal-title":"J Bone Miner Res"},{"key":"2692_CR27","unstructured":"Brown JP, Deal C, de Gregorio LH et al (2008) Effect of denosumab vs alendronate on bone turnover markers and bone mineral density changes at 12\u00a0months based on baseline bone turnover level [Abstract 1285]. J Bone Miner Res 23(Suppl S1):S80"},{"issue":"Suppl 1","key":"2692_CR28","first-page":"S123","volume":"27","author":"P Miller","year":"2012","unstructured":"Miller P, Gruntmanis U, Boonen S, Yang Y, Wagman R, Hall J, Orwoll E (2012) The effect of denosumab on bone mineral density (BMD) assessed by baseline bone turnover in men with low BMD [Abstract FR0393]. J Bone Miner Res 27(Suppl 1):S123","journal-title":"J Bone Miner Res"},{"key":"2692_CR29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"2692_CR30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"2692_CR31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","volume":"27","author":"M Austin","year":"2012","unstructured":"Austin M, Yang YC, Vittinghoff E et al (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27:687\u2013693","journal-title":"J Bone Miner Res"},{"key":"2692_CR32","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886\u20131894","journal-title":"J Bone Miner Res"},{"key":"2692_CR33","unstructured":"Zebaze RM, Libanati C, McClung MR, Zanchetta JR, Kendler DL, H\u00f8iseth A, Wang A, Ghasem-Zadeh A, Seeman E (2013) Denosumab reduces hip cortical porosity in women with osteoporosis [Abstract 1065]. J Bone Miner Res 28(Suppl S1):S23"},{"key":"2692_CR34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","volume":"49","author":"MS Ominsky","year":"2011","unstructured":"Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ (2011) Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 49:162\u2013173","journal-title":"Bone"},{"key":"2692_CR35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"2692_CR36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-014-2692-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2692-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T22:34:07Z","timestamp":1597617247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-014-2692-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,28]]},"references-count":36,"alternative-id":["2692"],"URL":"https:\/\/doi.org\/10.1007\/s00198-014-2692-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,28]]}}}